We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

15% more funds holding

Funds holding: 102 → 117 (+15)

3.77% more ownership

Funds ownership: 48.64% → 52.41% (+3.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less capital invested

Capital invested by funds: $140M → $125M (-$14.9M)

Holders
117
Holders Change
+15
Holders Change %
+14.71%
% of All Funds
2.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
40
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BC
Broadwood Capital
New York
+$6.72M
2
Axa
Axa
France
+$5.74M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.02M
4
Deutsche Bank
Deutsche Bank
Germany
+$1.53M
5
AG
Artal Group
Luxembourg
+$686K

Top Sellers

1
FM
Family Management
New York
-$374K
2
NFA
Nationwide Fund Advisors
Ohio
-$237K
3
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$164K
4
DWM
Destination Wealth Management
California
-$162K
5
Group One Trading
Group One Trading
Illinois
-$62.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
$64.4M +$6.72M +3,077,307 +10%
BlackRock
2
BlackRock
New York
$11.4M +$482K +220,644 +4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$8.84M +$478K +218,713 +5%
Axa
4
Axa
France
$4.94M +$5.74M +2,627,392 New
PGP
5
Prescott General Partners
Florida
$3.98M – – –
AG
6
Artal Group
Luxembourg
$3.35M +$686K +314,325 +21%
State Street
7
State Street
Massachusetts
$2.99M +$82.9K +37,959 +2%
Renaissance Technologies
8
Renaissance Technologies
New York
$2.58M +$2.02M +922,972 +207%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$2.37M +$85.3K +39,047 +3%
Deutsche Bank
10
Deutsche Bank
Germany
$2.2M +$1.53M +702,824 +150%
Northern Trust
11
Northern Trust
Illinois
$1.98M +$127K +58,153 +6%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$1.42M +$493K +225,597 +43%
DWM
13
Destination Wealth Management
California
$1.13M -$162K -74,295 -11%
IA
14
IndexIQ Advisors
New York
$878K +$392K +179,546 +63%
MHP
15
Manatuck Hill Partners
Connecticut
$756K – – –
Two Sigma Investments
16
Two Sigma Investments
New York
$622K +$398K +182,218 +123%
DCM
17
DAFNA Capital Management
California
$591K +$686K +314,325 New
Morgan Stanley
18
Morgan Stanley
New York
$552K +$235K +107,495 +58%
GPCM
19
Granite Point Capital Management
Massachusetts
$494K +$462K +211,455 +415%
TCIM
20
TIAA CREF Investment Management
New York
$436K +$47.5K +21,755 +10%
GCP
21
GSA Capital Partners
United Kingdom
$359K -$20K -9,144 -5%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$337K – – –
TA
23
Teachers Advisors
New York
$332K – – –
Millennium Management
24
Millennium Management
New York
$324K +$340K +155,683 +938%
Citadel Advisors
25
Citadel Advisors
Florida
$320K +$207K +95,014 +127%
1
2 3 4 5

LCTX Hedge Fund Activity: Q4 2017 in Review

117 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2017, worth a combined $125M — down 11% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LCTX positions and 7 closed out — a net gain of 16 holders — while 40 added to existing stakes and 18 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $6.72M. The largest seller was Family Management, cutting an estimated $374K.

  • 117 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2017, up from 102 in Q3 2017.
  • Funds reported $125M of Lineage Cell Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 23 funds opened new Lineage Cell Therapeutics positions in Q4 2017 and 7 closed out, a net change of +16 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2017 was Broadwood Capital, an estimated $6.72M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2017 was Family Management, an estimated $374K sold.

Based on aggregated 13F filings for Q4 2017.